Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 16:50
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
The best VPNs in September 2023
It's time for MySpace to make a comeback
Twitter's API keeps breaking, even for developers paying $42,000
China's Spy Balloon Was Full of US Tech, Chinese Sensors
AI risks repeating social media era's mistakes: Microsoft president
Fortnite Chapter 1 Map Release Date Confirmed
U.S. East Coast blanketed in eerie veil of smoke from Canada fires
Does deleting your Threads account also delete your Instagram?